Wangchinda Walaiporn, Srisompong Jintana, Chayangsu Sunee, Ruangkriengsin Darat, Thamlikitkul Visanu, Koomanachai Pornpan, Sirijatuphat Rujipas, Rattanaumpawan Pinyo
Department of Medicine, Division of Infectious Diseases and Tropical Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
Internal Medicine Unit, Surat Thani Hospital, Surat Thani 84000, Thailand.
Antibiotics (Basel). 2022 Mar 7;11(3):354. doi: 10.3390/antibiotics11030354.
Implementing antimicrobial stewardship (AMS) at non-university hospitals is challenging. A quasi-experimental study was conducted to determine the impact of customised antibiotic authorisation implementation on antimicrobial consumption and clinical outcomes at three provincial hospitals in Thailand. Customised pre-authorisation of selected restricted antibiotics and post-authorisation of selected controlled antibiotics were undertaken and implemented at each hospital by the local AMS team with guidance from the AMS team at the university hospital. From January 2019−December 2020, there were 1802 selected patients (901 patients during the pre-implementation period and 901 patients during the post-implementation period). The most commonly used targeted antimicrobial was meropenem (49.61%), followed by piperacillin/tazobactam (36.46%). Comparison of the outcomes of the patients during the pre- and post-implementation periods revealed that the mean day of therapy of the targeted antimicrobials was significantly shorter during the post-implementation period (6.24 vs. 7.64 days; p < 0.001), the favourable clinical response (the improvement in all clinical and laboratory parameters at the end of antibiotic therapy) was significantly higher during the post-implementation period (72.70% vs. 68.04%; p = 0.03) and the mean length of hospital stay was significantly shorter during the post-implementation period (15.78 vs. 18.90 days; p < 0.001). In conclusion, implementation of antibiotic authorisation at provincial hospitals under experienced AMS team’s guidance was feasible and useful. The study results could be a good model for the implementation of customised AMS strategies at other hospitals with limited resources.
在非大学附属医院实施抗菌药物管理(AMS)具有挑战性。一项准实验研究旨在确定定制抗生素授权实施对泰国三家省级医院抗菌药物使用及临床结局的影响。在大学医院AMS团队的指导下,当地AMS团队在每家医院对选定的限制使用抗生素进行定制预授权,并对选定的控制使用抗生素进行授权后管理。2019年1月至2020年12月,共纳入1802例选定患者(实施前阶段901例患者,实施后阶段901例患者)。最常用的目标抗菌药物是美罗培南(49.61%),其次是哌拉西林/他唑巴坦(36.46%)。实施前后患者结局比较显示,实施后阶段目标抗菌药物的平均治疗天数显著缩短(6.24天对7.64天;p<0.001),实施后阶段良好临床反应(抗生素治疗结束时所有临床和实验室参数均改善)显著更高(72.70%对68.04%;p=0.03),且实施后阶段平均住院时间显著缩短(15.78天对18.90天;p<0.001)。总之,在经验丰富的AMS团队指导下,省级医院实施抗生素授权是可行且有用的。该研究结果可为其他资源有限的医院实施定制化AMS策略提供良好范例。